Floatz logo

Infliximab

Metabolic Syndrome

Medical University of Grazmonoclonal_antibodyPhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

57 Active assets in the Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Metformin
Islamabad Medical and Dental College
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
OLMESARTAN MEDOXOMIL
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB

View all 50 →

Same molecule, other indications

Infliximab is also rated in:

CachexiaDormant
BB
Indicative ·
64 / 100
View asset →
hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →